|
MechanismCav2.1 inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.Sweden |
First Approval Date28 Mar 1998 |
100 Clinical Results associated with Dexcel Pharma GmbH
0 Patents (Medical) associated with Dexcel Pharma GmbH
100 Deals associated with Dexcel Pharma GmbH
100 Translational Medicine associated with Dexcel Pharma GmbH